Objective: Coverage of an accessory renal artery (ARA) during endovascular aneurysm repair (EVAR) may result in renal infarction (RI) or decline in renal function. Until now, it remains vague which patients are at risk to develop these complications. We therefore analyzed the effect of ARA sealing by EVAR with respect to the occurrence of RI and renal function.
During the last decades, treatment of infrarenal abdominal aortic aneurysms (AAA) has undergone an astonishing progress through the development of endovascular aneurysm repair (EVAR). 1, 2 Preoperative imaging mainly based on serial contrast-enhanced computed tomography (CT) is important to plan EVAR and to identify patients with unusual arterial anatomy. 3 An accessory renal artery (ARA) represents the most common, clinically important renal vascular variant and can be found in up to one-third of all patients. 4, 5 For surgical repair, ARAs arising inferior to the renal artery are of particular importance because the presence of an ARA arising from the sealing zone of the stent or aneurysm sac requires coverage by the stent graft or coil embolization during EVAR. 3 Because EVAR has been linked to renal impairment owing to administration of contrast media and endoluminal manipulations, sealing of an ARA may further affect renal function. 3, 6 Therefore, the Society of Vascular Surgery Consensus statement for AAA treatment recommends the preservation of ARAs with a diameter of greater than or equal to 3 mm or ARAs supplying more than one-third of the renal parenchyma. 7 Previous published data suggest that sealing of ARA during EVAR seems to be a safe procedure in terms of postoperative outcome. 3, 6, [8] [9] [10] However, some of these reports did not include a control group of patients without ARA undergoing EVAR, 6,9,10 whereas others show considerable differences within the groups of patients with and without ARA. 5, 10 Furthermore, these studies are controversial regarding the role of ARAs with respect to renal infarction (RI) and development of an endoleak. 3, 6, [8] [9] [10] Consequently, we analyzed the effect of ARA sealing by EVAR with respect to the occurrence of RI and renal function (as predicted by the estimated glomerular filtration rate [eGFR] ). Within the study, we compared the postoperative course of patients with infrarenal AAA and ARA to a matched group of patients (age, gender, eGFR, and applied contrast media) without ARA undergoing EVAR. Furthermore, in the group of patients with ARA undergoing EVAR we assessed postoperative renal function with respect to preoperative renal function (normal or impaired). Finally, we determined whether the size of ARAs is associated with the occurrence of RI.
METHODS
The study followed the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the Ludwig Maximilians University Munich (approval number: 65-16). Because our analysis was retrospective, a specific informed consent for this study was (in accordance to the Institutional Review Board) not necessary. We performed a retrospective review of the medical records of patients who underwent EVAR within a period of 5 years. During this period no changes were done with respect to the EVAR procedure, postoperative management, or the used prosthesis. Only patients with intact aneurysms were analyzed; patients with infected or ruptured aneurysms were excluded. Patients with symptomatic and asymptomatic aneurysms were included. Patients with renal artery stenosis as well as stenosis of the ARA, single function kidney, hemodialysis, kidney transplant, and pararenal aneurysm were excluded. Patient demographics, medical histories, and laboratory results were abstracted from medical records.
Biphasic CT angiography was performed before surgery, postoperatively before discharge and during follow-up after 6 months. Contrast media (Ultravist 370; Bayer Vital GmbH, Leverkusen, Germany) was administered according to weight with a maximum volume of 120 mL. In cases of preprocedural impaired renal function (IF) hydration therapy in accordance with the European Society of Urogenital Radiology guidelines was administered. 11 Presence of ARA was confirmed by preprocedural CT scan. CT scans were evaluated with respect to aneurysm diameter, accessory renal arteries, and diameter of the ARA. Endograft coverage of the ARA was documented by angiography and follow-up CT scans. Follow-up CT scans were evaluated with respect to postoperative contrast enhancement and segmental RIs. All diameters were measured close to the origin from the aneurysm. The endovascular procedure was performed in the operating room by two experienced vascular surgeons under either general or epidural anesthesia. We used sufentanile (0.3-0.5 mg/kg) and propofol (1-2.5 mg/kg) for induction of general anesthesia and remifentanile (10-20 mg/kg/h) and propofol (6-8 mg/kg/h) for maintenance. Epidural anesthesia was performed with a loss of resistance technique and injection of approximately 10 mL of ropivacaine 1% and 10 mg sufentanile, followed by repetitive administration of 1 to 2 mL Ropivacaine 1%. Additional small doses of intravenous Midazolam were used in patients if needed. The procedural details of EVAR have been described in detail by Moore et al. 12 The amount of contrast media used during EVAR was documented. Serologic parameters were routinely obtained the day before and after EVAR, 1 week after EVAR, as well as during follow-up after 6 months. Serum creatinine levels were measured and the eGFR was calculated according to the Modification of Diet in Renal Disease equation.
Of a total of 207 patients, 34 patients underwent EVAR with coverage of ARA. These patients were matched 1:3 according to age, gender, amount of contrast media used during EVAR, and eGFR with 102 patients undergoing EVAR without having an ARA. We allowed a deviation of 20% in age, amount of used contrast media, and eGFR before EVAR. Statistical analysis was performed using SigmaStat 12.0 (Systat Software, Chicago, Ill) and Stata 13 (College Station, Tex). Analysis was started by testing for normal distribution using the Shapiro-Wilk test. Testing for differences between groups was accomplished by the Student t test for all data with normal distribution and the nonparametric Mann-Whitney rank sum test for all data without normal distribution. Discrete variables were compared with the c 2 or Fisher exact test, when appropriate. In a second approach, we investigated differences between ARA and non-ARA patients using multivariable multilevel regression with random effect to correct for clustering on the individual level to account for repeated measurements and to adjust for possible confounders. We log transformed eGFR and creatinine for this approach. After performing a univariate model (no adjustment), in a second model we adjusted for hypertension (yes/no), diabetes (yes/no), hyperlipidemia (yes/no), coronary artery disease (yes/no), chronic obstructive pulmonary disease (yes/no), and smoking (yes/no). Finally, we stratified the data for the different time points of measurement, performing adjusted and unadjusted regression analysis. P < .05 was considered significant. Results are expressed as medians and 25th to 75th percentiles unless stated otherwise.
RESULTS
The median age of the 34 patients with ARA undergoing EVAR was 74 years [68/79] and the median diameter of the ARA was 3.0 mm [2.5/4]. Further characteristics are listed in Table I . The majority of analyzed patients also presented comorbidities including arterial hypertension, hyperlipidemia, heart diseases, peripheral artery occlusive diseases, and diabetes. These comorbidities did not differ significantly between the two groups. None of the patients had a history of renal insufficiency or hemodialysis before the procedure. The number of patients showing a significant thrombus (>40% of the aortic neck circumference) in the neck of the aneurysm did not differ between the analyzed groups (patients with Fig 1) .
Results could be confirmed in a multilevel analysis, taking into account multiple measurements in patients.
We found a significant difference in eGFR during follow-up after EVAR between patients with ARA and non-ARA patients, the effect remained stable if adjusted for possible confounders (coefficient, À0.09; 95% confidence interval, 0.18 to À0.01; P ¼ .04). However, if stratified for different times after EVAR, we found that the effect was mainly driven by the later measurements, the difference in eGFR between the two groups was only significant at 1 week and 6 months after surgery Table III. RI after EVAR. Coverage of the ARA was necessary in 21 cases (62%) because of its location at the proximal landing zone and in 13 cases (38%) because of its origin from the aneurysm sac. RI was detected after EVAR in 17 patients (50%) with ARA and in none patient without ARA (0%; P < .001). The location of RI detected on the postoperative CT scan was matched to the supply area of the covered ARA. The diameter of ARA in patients who developed RI was not different from the diameter of ARA in patients without RI (3.5 
DISCUSSION
Within this study, we analyzed the renal function of patients with infrarenal AAA with or without ARA after EVAR. We found a more pronounced reduction in renal function in patients with ARA after EVAR when compared with patients without ARA. This decrease was found within 1 week after EVAR and did not change after 6 months. The decrease in renal function of patients with ARA after EVAR was significantly pronounced in patients with preoperative NF as estimated by an eGFR of 60 mL/min or greater when compared with patients with IF (eGFR < 60 mL/min). Furthermore, patients with an infrarenal AAA and ARA who developed RI after EVAR showed a significant decrease in renal function when compared with patients with infrarenal AAA and ARA without RI after EVAR.
Previous studies demonstrated that sealing of ARA by EVAR does not impair renal function significantly. 3, 8, 13 However, the different reports presented conflicting data. Greenberg et al 8 and Malgor et al 3 reported no change in eGFR in patients with EVAR and ARA within the first 24 or 36 months, respectively, after intervention, whereas Antonello et al 13 reported a decrease in renal function in patients with ARA after EVAR. In our study population, we also found a slight but significant decrease in renal function in patients with ARA after EVAR. There are two reasons that may explain these differences. First, different factors such as renal impairment (before EVAR), advanced age, gender, and the amount of used contrast media have been responsible for the decline in renal function after intervention. 13, 14 These factors have only been partly considered by different research groups 3, 8, 13 when composing their study population and may therefore explain the conflicting results in part. In our study, we have excluded these factors being responsible for a decline in renal function by matching patients with ARA to patients without ARA with respect to the mentioned factors. Second, we found a more pronounced decrease of eGFR in patients with ARA and NF before EVAR. If one compares previous studies, it is apparent that eGFR before EVAR differs significantly between these studies. 3, 13 Although patients' renal function was impaired in the study of Malgor et al 3 (no change in eGFR during follow-up), the patients in the study of Antonella et al 13 had a NF before EVAR (reduction of eGFR during follow-up). Our results may explain this varying data, because the decrease of eGFR was significantly distinct in patients with ARA and NF before EVAR. Therefore, ARA seems to be a risk factor for impairment of renal function after EVAR in patients with ARA and NF before operation. Recent studies have focused on the evaluation of renal function in patients with ARA after EVAR who showed renal dysfunction before EVAR. 3, 9 The authors of these studies did not observe a change in renal function during follow-up in these patients. 3, 9 Although some patients showed a worsening of parameters of renal function during the first days after EVAR, these parameters returned to baseline during follow-up. 3, 9 Based on these observations, researchers concluded that ARA coverage is a safe procedure. 3, 9 Nevertheless, Karmacharya et al 9 reported that all patients with infrarenal AAA and ARA received perioperative renal protection consisting of vigorous hydration, osmotic diuretics, and reduction or avoidance of contrast media. We also detected no changes in renal function in patients with ARA and IF before EVAR. Surprisingly, patients with NF and ARA before EVAR presented a significant decrease in renal function. Reports dealing with compensatory mechanisms in patients with IF describe well-developed compensatory abilities in these patients. 15, 16 These compensatory abilities result at least partly from the development of compensatory tubular cell hypertrophy triggered by transforming growth factor-b. 16 The postulated compensatory mechanisms in patients with impaired preoperative renal function may explain the minimal changes in eGFR during follow-up after sealing of an ARA with EVAR. Furthermore, the compensatory mechanism of the kidney may also explain why there is no further decline in renal function during follow-up after 6 months. Even though the decrease in renal function did not achieve critical values in patients with preoperatively NF, one should be alert to avoid nephrotoxic substances and prolonged episodes of hypotension during EVAR to prevent a further decrease in renal function. RI after coverage of an ARA during EVAR can be detected in a large number of cases. 6, 8, 9 The volume of RI is significantly different in patients with ARA coverage compared with those with ARA preservation. 8 This observation suggests that ARAs seem to supply a small parenchymal area of the kidney and act as an end artery. 8 It has been speculated that the occurrence of RI is owing to the size of the ARA 6 and the Society of Vascular Surgery Consensus statement recommends preservation or reimplantation of ARAs of 3 mm or greater in patients with infrarenal AAA repair. 7 Greenberg et al 8 did not find a significant decrease in renal function in patients with covered ARAs larger than 3 mm. In our analysis, we also did not detect an increased diameter of ARAs in the group with RI after EVAR. Furthermore, there was no correlation of ARA size and the development of RI. However, we found a significantly negative effect of RI on postoperative eGFR starting 1 week after intervention, which remained impaired 6 months after EVAR. This finding suggests that no effective compensatory mechanism exist to prevent a decline in renal function in the setting of an acute RI. Our study has some obvious limitations. Data collection was obtained in a retrospective design and can therefore be influenced by differences in daily clinical practice. However, our patients were consistently treated according to standard protocols. This might reduce this potential source of error. Owing to the incidence of patients with infrarenal AAA and ARA, the number of cases included in this study is low but comparable with previous studies. However, the presented data must be interpreted in this context.
CONCLUSIONS
The decrease in renal function was more pronounced in patients with ARA after EVAR when compared with patients without ARA undergoing EVAR. In patients with ARA, the observed decline in renal function was significantly distinct in patients presented with NF preoperatively. To prevent a critical decrease in renal function, one should be alert to avoid nephrotoxic substances in those patients. 
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